The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | The potential of ctDNA in monitoring disease progression in metastatic colorectal cancer
Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of circulating tumor (ctDNA) in monitoring disease progression in metastatic colorectal cancer (mCRC). While acknowledging the promise of ctDNA, Dr Raghav highlights challenges such as the lack of standardized assays and the need for more randomized trials to establish appropriate cutoffs and testing intervals. Despite these hurdles, he expresses optimism about the future integration of ctDNA monitoring into regular clinical practice, emphasizing its potential to enhance precision care in mCRC. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role – Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding – Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
